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CSF1, also known as M-CSF, regulates the sur-
vival, proliferation, differentiation, and chemo-
taxis of cells of the monocyte/macrophage 
lineage (Pixley and Stanley, 2004; Hamilton, 
2008). It is produced by multiple cell types, 
including monocytes/macrophages, endothelial 
cells, fibroblasts, and bone marrow stromal cells 
(Pixley and Stanley, 2004; Chitu and Stanley, 
2006; Hamilton, 2008). The biological effects of 
CSF1 are mediated by a single CSF1 receptor 
(CSF1R), which is encoded by the c-fms proto-
oncogene (Sherr et al., 1985). The receptor is 
largely restricted to mononuclear phagocytes, 
although it has been detected on oocytes, tro-
phoblasts, and certain lymphocytes (Pixley and 
Stanley, 2004; Chitu and Stanley, 2006; Hamilton, 
2008). Ligand binding to CSF1R in macro-
phages triggers multiple signal transduction 
pathways resulting in activation of AKT and 
cAMP responsive element–binding protein 
(CREB) and mitogen-activated protein kinase 
(Hamilton, 1997; Pixley and Stanley, 2004).
The importance of CSF1 has been demon-
strated by studies with the CSF1-null mutant os-
teopetrotic (Csf1op/op) mouse (Wiktor-Jedrzejczak 
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Colony-stimulating factor 1 (CSF1) and interleukin-34 (IL-34) are functional ligands of 
the CSF1 receptor (CSF1R) and thus are key regulators of the monocyte/macrophage 
lineage. We discovered that systemic administration of human recombinant CSF1 amelio-
rates memory deficits in a transgenic mouse model of Alzheimer’s disease. CSF1 and IL-34 
strongly reduced excitotoxin-induced neuronal cell loss and gliosis in wild-type mice when 
administered systemically before or up to 6 h after injury. These effects were accompanied 
by maintenance of cAMP responsive element–binding protein (CREB) signaling in neurons 
rather than in microglia. Using lineage-tracing experiments, we discovered that a small 
number of neurons in the hippocampus and cortex express CSF1R under physiological 
conditions and that kainic acid–induced excitotoxic injury results in a profound increase in 
neuronal receptor expression. Selective deletion of CSF1R in forebrain neurons in mice 
exacerbated excitotoxin-induced death and neurodegeneration. We conclude that CSF1 
and IL-34 provide powerful neuroprotective and survival signals in brain injury and neuro-
degeneration involving CSF1R expression on neurons.
© 2013 Luo et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
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CSF1R protein in these cells in vivo has not been demon-
strated conclusively, and results from immunohistochemi-
cal studies are inconsistent and contradictory (Murase and 
Hayashi, 1998; Raivich et al., 1998; Wang et al., 1999; Murphy 
et al., 2000). Furthermore, no functional data supporting an 
in vivo role of CSF1R in neurons are available. In spite of 
cell culture studies showing CSF1 production in different 
CNS cells, the source of CSF1 in the CNS has not been un-
equivocally located.
Using CSF1R reporter mice and genetic deletion of 
CSF1R in neurons, we demonstrate a critical protective and 
survival function of this receptor in neurons in a model of 
excitotoxic neurodegeneration. Importantly, systemic CSF1 
and IL-34 administration is sufficient to exert similar benefi-
cial effects even hours after the neuronal insult, supporting 
their potential importance in recovery from neuronal injury.
RESULTS
Systemic administration of CSF1 improves cognitive 
function in human amyloid precursor protein (hAPP) 
transgenic mice, independent of A pathology
We have previously reported that CSF1 was reduced in AD 
plasma (Ray et al., 2007; Britschgi et al., 2011), and CSF1 has 
been shown to reduce AD-like disease in mice (Boissonneault 
et al., 2009). To better understand the role of CSF1 in neu-
rodegeneration, we injected human CSF1 or PBS i.p. into 
6-mo-old hAPP transgenic mice (Rockenstein et al., 2001) and 
their nontransgenic (nTG) littermates at a dose of 800 µg/kg 
body weight, similar to what has been used clinically in bone 
marrow transplantation patients (Nemunaitis et al., 1993). 
After 10 wk of treatment, mice were assessed for learning and 
memory function using the Morris water maze. CSF1-treated 
hAPP mice showed significantly better behavioral outcomes 
than PBS-injected hAPP mice, as indicated by shorter escape 
latencies in the hidden platform tests (Fig. 1 A). In addition, to 
determine whether CSF1 could improve memory function in 
animals already exhibiting behavioral deficits (Fig. 1, B and C) 
and whether a shorter period of treatment exerts similar 
effects, we injected CSF1 or PBS into 18–20-mo-old hAPP 
and nTG mice for 4 wk. CSF1 treatment significantly re-
duced memory deficits in hAPP mice in the hidden platform 
test (Fig. 1 D) and the probe trial (Fig. 1 E). Thus, CSF1 
treatment ameliorates learning and memory deficits in hAPP 
transgenic mice.
To determine whether CSF1 exerts its effect by altering 
A accumulation or aggregation in the brain, we measured 
A levels by immunoreactivity and amyloid by thioflavin S 
staining (sections from the 6-mo-old hAPP mice that were 
treated with CSF1 for 10 wk, as shown in Fig. 1 A). No sig-
nificant differences were observed in the hippocampus in 
either of these measures between CSF1- or PBS-treated hAPP 
mice (percentage of area occupied by A immunoreactivity 
[anti–A1-5] was 4.670 ± 0.811% in CSF1-treated hAPP 
mice vs. 4.141 ± 0.874% in PBS-injected group, P = 0.333 
by Student’s t test; percentage of area covered by thioflavin S 
was 0.703 ± 0.143% in CFS1-treated and 0.792 ± 0.146% in 
et al., 1990; Yoshida et al., 1990). Homozygous Csf1op/op 
mice lack functional CSF1 and display pleiotropic phenotypes, 
including osteopetrosis and reduced numbers of tissue mac-
rophages. These phenotypes are rescued by expression of a 
CSF1 transgene (Ryan et al., 2001), confirming that the ab-
sence of CSF1 is responsible for the abnormalities. Further-
more, targeted ablation of CSF1R largely recapitulates the 
pathology seen in Csf1op/op mice (Dai et al., 2002), indicating 
that the effects of CSF1 are mediated by this single receptor. 
More recently, IL-34 was identified as a second ligand for 
CSF1R (Lin et al., 2008), but little is known about its biol-
ogy and capacity to substitute for CSF1. In cultured macro-
phages, IL-34 shows an equivalent ability to support cell 
growth and survival as CSF1; however, it may interact with 
distinct regions of CSF1R (Garceau et al., 2010) and initiate 
different biological activities and signal activation (Chihara 
et al., 2010; Wei et al., 2010; Liu et al., 2012).
CSF1 levels are increased in brains from patients with 
Alzheimer’s disease (AD), HIV-1 encephalitis, or brain tumors 
and in several experimental brain injury models (Imai and 
Kohsaka, 2002; Chitu and Stanley, 2006), but few studies 
have dissected the functional role of this factor in central ner-
vous system (CNS) disease. Consistent with its role in regu-
lating the monocyte/macrophage lineage, CSF1R is expressed 
in microglia in the CNS (Raivich et al., 1998), and CSF1 is 
crucial for maturation of these cells (Imai and Kohsaka, 2002). 
Indeed, CSF1-null Csf1op/op mice have fewer microglia and 
show impaired microglial activation in response to injury 
(Berezovskaya et al., 1995). CSF1R expression is enhanced 
in activated microglia surrounding plaques in AD and in 
transgenic mouse models of AD (Murphy et al., 2000), and 
brain CSF1 levels were reported to be higher in AD com-
pared with nondemented controls (Du Yan et al., 1997). 
Although these studies imply that CSF1 may have a role in 
CNS function and disease, its mode of action remains un-
clear. Because CSF1 synergizes with fibrillar A to induce 
neurotoxicity in co-cultures of microglia with primary neu-
rons (Li et al., 2004), CSF1 has been suggested to promote 
detrimental inflammatory processes in the AD brain (Murphy 
et al., 1998) and in a mouse model of amyotrophic lateral 
sclerosis (Gowing et al., 2009). In contrast, CSF1 enhances 
survival of Purkinje cells and cortical neurons cultured in 
serum-free medium (Murase and Hayashi, 1998; Wang et al., 
1999) and reduces N-methyl-d-aspartic acid (NMDA)–
induced neuronal cell death in hippocampal slices (Vincent 
et al., 2002). Recombinant CSF1 delivered in implanted mi-
crocapsules in the peritoneum protects against ischemic 
injury (Berezovskaya et al., 1996). Similarly, in an AD mouse 
model, treatment with recombinant CSF1 improved cogni-
tive performance (Boissonneault et al., 2009). This opens the 
question of whether CSF1 has neuroprotective functions and 
targets cells other than microglia in the CNS. In support of 
this notion, CSF1R mRNA has been detected in cultured 
astrocytes, oligodendrocytes, and neurons using RT-PCR 
and in situ hybridization (Sawada et al., 1993; Murase and 
Hayashi, 1998; Wang et al., 1999). However, the presence of 
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and has been implicated in various neurodegenerative diseases 
including AD (Mattson, 2004). We administered CSF1 sys-
temically in a mouse model of KA-induced excitotoxicity. To 
induce consistent excitotoxic neurodegeneration, KA was 
administered either systemically (subcutaneously) in FVB/N 
mice or stereotaxically into the hippocampus in C57BL/6 mice 
(Fig. 2 A). We first used bioluminescence imaging, which en-
abled us to follow astrocyte activation (astrogliosis) and neuro-
degeneration in reporter mice expressing luciferase under the 
control of a glial fibrillary acidic protein (GFAP) promoter 
(GFAP-luc mice; Zhu et al., 2004; Luo et al., 2007). Neuronal 
injury is closely tied to astrogliosis, and KA-induced biolumi-
nescence in GFAP-luc mice correlates significantly with hip-
pocampal cell death (Zhu et al., 2004). We used this technique 
to take advantage of testing a relatively large number of po-
tentially therapeutic conditions in a medium throughput 
manner while studying individual mice throughout the course 
of injury (Fig. 2 A). KA lesion (subcutaneous administra-
tion) in the reporter mice led to a reproducible, significant 
increase in bioluminescence in the brain (Fig. 2, B and C). 
Notably, systemic CSF1 pretreatment (800 µg/kg body weight) 
at 24 or 2 h before KA administration significantly inhibited 
astrogliosis at days 3 and 5 (Fig. 2, B and C). To determine the 
potential clinical relevance of our findings, we tested whether 
systemic administration of CSF1 could be used to reduce neu-
rodegeneration after an injurious insult had occurred. Mice 
receiving CSF1 (800 µg/kg body weight) at 2 or 6 h (but not 
12 h) after KA showed similar and significant reduction of 
astrogliosis (Fig. 2 D).
Reduced neurodegeneration with CSF1 treatment was 
confirmed by pathological analysis of brains, with examples 
shown for CSF1 applied before or after KA injection (Fig. 3). 
KA (subcutaneous administration) resulted in significant de-
generation of neurons in the pyramidal layer (Fig. 3 A) and re-
duced hippocampal calbindin immunoreactivity (Fig. 3 C) 
upon postmortem pathological examination, consistent with a 
previous study (Luo et al., 2006). In contrast, mice injected i.p. 
with recombinant human CSF1 24 h before KA showed little 
hippocampal cell loss (Fig. 3, A and B) and calbindin reduction 
(Fig. 3, C and D), although they suffered from similar seizure 
activity (highest seizure score 6.2 ± 1.7 in CSF1-treated group 
vs. 6.4 ± 1.3 in PBS-treated group). In line with these findings, 
systemic CSF1 administration significantly reduced the increase 
in levels of neuropeptide Y (NPY) in the hippocampus associ-
ated with KA lesioning (Fig. 3, E and F). Consistent with in 
vivo imaging, CSF1 administered up to 6 h after KA led to 
similar and significant reduction of neurodegeneration (Fig. 3, 
K and L). Thus, systemic administration of CSF1 attenuates 
KA-induced excitotoxic neurodegeneration and provides sig-
nificant neuroprotection.
Strong neuroprotective effects of systemically  
administered IL-34
Recently, IL-34 has been identified as a second ligand for 
CSF1R (Lin et al., 2008). To determine whether IL-34 pro-
vides neuroprotection against excitotoxic injury as well we 
PBS-injected animals, P = 0.335 by Student’s t test). Further-
more, we measured both soluble and insoluble levels of A1-x 
and A1-42 by ELISA and observed no significant changes 
in hippocampus or cortex of hAPP mice after CSF1 treat-
ment (not depicted). These findings show that in contrast to 
previous findings in another AD mouse model (Boissonneault 
et al., 2009), the beneficial effects of CSF1 on cognitive func-
tion in the hAPP mice tested here are likely independent of 
A accumulation.
Systemic administration of CSF1 reduces kainic acid  
(KA)–induced neuroinflammation and neurodegeneration
Because CSF1 did not seem to affect A load in hAPP mice, 
we asked whether it might exert protective effects on neu-
rons and thereby ameliorate cognitive deficits. To explore 
this possibility, we used a model of excitotoxicity, which is 
thought to represent a common pathway of neuronal demise 
Figure 1. Systemic CSF1 improves cognitive function in hAPP 
transgenic mice. (A) hAPP transgenic mice and their nTG littermates (n = 
9–10 mice per genotype, age 5.5–6.5 mo) were injected with 800 µg/kg 
CSF1 or PBS three times a week. After 10 wk of treatment, spatial cog-
nitive function in mice was assessed using the Morris water maze.  
(B–E) hAPP mice and nTG littermates (18–20 mo old) were assessed by 
water maze in hidden platform tests (B) and a probe trial 24 h later (C). 
The mice were then randomly divided into CSF1 or PBS groups (n = 6–8 mice 
per genotype). After 1 mo of treatment, mice were tested again with a 
water maze hidden platform test (D) and a probe trial (E). The target 
quadrant was quadrant 1 in C and E. Bars are mean ± SEM. *, P < 0.05; 
**, P < 0.01 compared by ANOVA and Bonferroni post-hoc test. Each 
experiment was performed once.
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administered recombinant IL-34 (100 µg/kg) systemically in 
FVB/N mice lesioned by KA (subcutaneous administration). 
Mice receiving IL-34 showed significantly reduced neuronal 
cell loss (Fig. 4, A, B, E, F) and calbindin reduction (Fig. 4, C 
and D) in the pyramidal cell layer of the hippocampus. Inter-
estingly, IL-34 administered 2 or 6 h after KA also provided 
significant reduction of neurodegeneration (Fig. 4, K and L). 
These results demonstrate that systemic administration of re-
combinant IL-34 attenuates excitotoxic injury and provides 
similar neuroprotection as recombinant CSF1.
CSF1 inhibits KA-induced microgliosis but does not induce 
the infiltration of peripheral (myeloid) cells into the brain
CSF1 is the primary regulator of the survival, proliferation, dif-
ferentiation, and function of cells of the monocyte/macrophage 
lineage (Pixley and Stanley, 2004; Hamilton, 2008). To inves-
tigate how microglia respond to KA injury and to CSF1 
treatment, the activation of microglia was analyzed as a func-
tion of CD68 expression (Luo et al., 2006). KA injection 
caused massive activation of microglia in the hippocampus, 
which was almost completely prevented by i.p. application of 
CSF1 (Fig. 3, G and H). Similar results were obtained when 
microglial activation was quantified with an antibody against 
the activation marker CD11b (immunoreactivity assessed by 
percentage of occupied area was 3.948 ± 0.1997% in KA/
CSF1 vs. 4.664 ± 0.04571% in KA/PBS group, P = 0.001 by 
Student’s t test). No significant difference was found in im-
munoreactivity for Iba-1, a marker which seems less sensitive 
to activation changes in microglia (Fig. 3, I and J; P = 0.569, 
KA/CSF1 vs. KA/PBS group). Similarly, no significant dif-
ference was found in Iba-1 immunoreactivity after IL-34 
treatment (Fig. 4, I and J).
To determine whether activated microglia originated from 
local resident cells or from the periphery and whether CSF1 
induced the infiltration of peripheral (myeloid) cells into the 
brain, we made use of parabiosis in which two mice share a 
common blood supply after being joined surgically at their 
flanks (Villeda et al., 2011). Wild-type or hAPP transgenic 
mice were paired with actin-EGFP transgenic mice (Okabe 
et al., 1997) and were analyzed for GFP+ cells in the brain 
6 wk later. In the control parabionts, which received no KA 
injury, there were few GFP+ cells in the brain (12.83 ± 2.18 
GFP+ cells/section), consistent with previous studies (Ajami 
et al., 2007; Villeda et al., 2011), and CSF1 treatment did not 
significantly increase the number of these cells (14.33 ± 2.43 
GFP+ cells/section, P > 0.05). Likewise, no significant dif-
ference was detected in the numbers of GFP+ cells in KA-
injected mice, with or without CSF1 treatment (15.50 ± 
2.42 GFP+ cells/section without CSF1 vs. 14.89 ± 3.41 GFP+ 
cells/section with CSF1, P > 0.05). These results are in 
Figure 2. Systemic administration of CSF1 inhibits KA-induced 
astrogliosis in reporter mice. (A) Experimental design and injury models 
of excitotoxicity. To induce excitotoxic neurodegeneration, KA was  
administered systemically (subcutaneously, SQ) in FVB/N and stereotaxi-
cally into the hippocampus in C57BL/6 mice. Neurodegeneration was 
analyzed 5 d later. To determine the effective time window of CSF1 and 
IL-34 application, CSF1 and IL-34 (single-bolus) were administered at 
different time points in relation to KA injury, 2 and 24 h before and 2, 6, 
and 12 h after KA administration. An example of one treatment (24 h 
before) is shown (top two panels). To study the time course of expression 
of endogenous CSF1 or its receptor, CSF1R, mice were analyzed at 6 h, 
24 h, 3 d, and 5 d (bottom). BLI, bioluminescence imaging. (B–D) GFAP-
luc mice (FVB/N background, 2 mo old) were lesioned with 20 mg/kg KA, 
and bioluminescence was recorded longitudinally at the indicated time 
points in each mouse. (B) Representative images from two independent 
experiments showing increased bioluminescence signals over the brain 
after KA injury (top) and the reduction by CSF1 treatment (applied 24 h 
before KA; bottom). (C and D) Bioluminescence is expressed as fold in-
duction over baseline in mice treated with CSF1 at 2 or 24 h before KA 
(C) or at 2, 6, or 12 h after KA (D). Baseline was measured 1 d before KA 
administration for each mouse. Bars are mean ± SEM (n = 4–7 mice). *, P < 
0.05 compared by ANOVA and Bonferroni post-hoc test. Each experiment 
(condition) was performed once in D.
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brain. In the uninjured brain, we observed faint CSF1 im-
munoreactivity throughout the brain, which was absent in 
CSF1-deficient Csf1op/op mice (Fig. 5 A), thus confirming 
specificity of the antibody. In contrast, KA administration led 
to a progressive increase of CSF1 immunoreactivity in the 
hippocampus, first in CA3 at 6 h and then throughout the 
hippocampus at 24 h (Fig. 5, A and B). Interestingly, CSF1 
immunoreactivity was localized mostly to neurons (Fig. 5 C, 
6 h after KA). Although CSF1 expression varied significantly 
among individual animals, immunoreactivity showed a re-
markable inverse correlation with neuronal cell loss at day 3 
(R = 0.731, P = 0.023; Fig. 5 D). In agreement with this 
inverse correlation between CSF1 expression and neurode-
generation, we found a striking lack of CSF1 immunoreac-
tivity in mice that died within 6 h after KA administration and 
were immediately dissected for analysis (n = 6 mice; Fig. 5 B). 
agreement with previous publications using different meth-
ods (Dommergues et al., 2003) and using mice with a differ-
ent genetic background (Ajami et al., 2007; Villeda et al., 
2011). In addition, similar results were obtained from hAPP 
parabionts. The number of GFP+ cells in the PBS-injected 
hAPP brain was 12.33 ± 1.60/section, and that in the CSF1-
treated brain was 11.33 ± 2.42/section (P > 0.05). In aggre-
gate, our findings suggest that CSF1 does not exert its 
protective effects by recruiting peripheral myeloid or other 
cells to the brain in the hAPP transgenic mice and the 5-d 
excitotoxicity paradigm.
Endogenous CSF1 is up-regulated in neurons after injury
To identify the potential target cell responsible for beneficial 
effects of CSF1 in the excitotoxicity model, we examined 
expression of endogenous CSF1 in the uninjured and injured 
Figure 3. Systemic CSF1 attenuates 
KA-induced neurodegeneration and  
microgliosis. (A–J) 2-mo-old FVB/N mice were 
lesioned with 20 mg/kg KA (subcutaneous 
injection) or injected with PBS as control 
and sacrificed 5 d later. Recombinant  
800 µg/kg CSF1 was injected i.p. once 24 h 
before KA. KA-induced neuronal injury was 
assessed by cresyl violet staining (A and B), 
calbindin immunostaining (C and D), and 
NPY immunostaining (E and F), and microg-
lial activation was assessed by CD68 (G and H) 
or Iba-1 (I and J) immunostaining. Repre-
sentative images from three independent 
experiments are shown from hippocampi of 
mice: control (nonlesioned, left) or KA  
lesioned and treated with PBS (middle) or 
CSF1 (right). Bars, 200 µm. (K and L) Sys-
temic administration of CSF1 after KA  
lesion reduces neurodegeneration. KA-lesioned 
mice were treated with CSF1 at 2, 6, and 12 h 
after injury. The mice were sacrificed at day 5. 
Excitotoxic injury was assessed by cresyl 
violet staining (K) and CD68 immunostain-
ing (L). Bars are mean ± SEM (n = 4–7 mice/
group). *, P < 0.05; **, P < 0.01 compared  
by ANOVA and Bonferroni post-hoc test. 
Similar results were obtained from two 
independent experiments.
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was a prominent induction of Csf1r mRNA 24 h after KA 
injury in the neuron-dense pyramidal cell layer (Fig. 6 B), sug-
gesting expression of Csf1r mRNA in cell types other than 
microglia. Importantly, no hybridization signal was observed 
in the sense control sections (Fig. 6, C and D). To identify 
the cell types that express CSF1R, we used a transgenic re-
porter mouse that expresses EGFP under control of the Csf1r 
promoter (Burnett et al., 2004). The expression of EGFP was 
detected with immunostaining using an anti-GFP antibody, 
which produced no immunostaining in brains of wild-type 
mice (Fig. 6 E). In contrast, we observed a broad, predomi-
nantly microglial expression pattern of the reporter gene 
throughout the normal, uninjured mouse brain (Fig. 6 E), in 
agreement with reports in the literature (Sherr et al., 1985; 
Raivich et al., 1998). Consistent with the mRNA in situ staining, 
Together, these results are consistent with the possibility that 
up-regulation of local CSF1 in the brain serves to protect 
neurons from degeneration and cell death.
CSF1R is expressed in neurons and up-regulated after injury
Next, we studied the expression of CSF1R in the brain. We 
first tested six different commercially available CSF1R anti-
bodies (for a list see Materials and methods), some of which 
had been used in the literature to stain brain tissues in the 
past, but found that none of them produced specific staining 
that was absent in CSF1R knockout mice (Li et al., 2006). 
We therefore used in situ hybridization to detect Csf1r mRNA. 
Using antisense probes to Csf1r, we found scattered stainings 
throughout the normal, uninjured mouse brain, including in the 
hippocampal CA1 and CA3 regions (Fig. 6 A). Notably, there 
Figure 4. Systemically administered IL-34 attenu-
ates KA-induced neurodegeneration and microgliosis. 
(A–J) 2-mo-old FVB/N mice were lesioned with 20 mg/kg 
KA (subcutaneous injection) and sacrificed 5 d later. 100 µg/kg 
IL-34 was injected i.p. once 2 h before KA. KA-induced 
neuronal injury was assessed by cresyl violet staining  
(A and B), calbindin (C and D), and NeuN (E and F) immuno-
staining, and microglial activation was assessed by  
CD68 (G and H) or Iba-1 (I and J) immunostaining. Repre-
sentative images from two independent experiments are 
shown from hippocampi of mice treated with PBS (left) or 
IL-34 (right). Bars, 200 µm. Bars in B, D, F, H, and J are 
mean ± SEM (n = 4 mice/group) from one out of two 
independent experiments. *, P < 0.05; **, P < 0.01 com-
pared by Student’s t test. (K and L) KA-lesioned mice were 
treated with IL-34 at 2 and 6 h after injury. The mice were 
sacrificed at day 5. Excitotoxic injury was assessed by 
NeuN immunostaining (K) and cresyl violet staining (L). 
The experiment was performed once. Bars are mean ± 
SEM (n = 5 mice/group). *, P < 0.05 compared by ANOVA 
and Bonferroni post-hoc test.
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injury was shown to selectively decrease phosphorylation 
of CREB (p-CREB) in vulnerable brain regions, but the cause 
for this decrease was not identified (Ferrer et al., 2002). Be-
cause CREB has a key function in neuronal survival (Walton 
and Dragunow, 2000), we reasoned that CSF1 might help 
maintain or restore CREB phosphorylation in neurons as 
well. Indeed, at 6 h after KA administration, p-CREB im-
munoreactivity was reduced in CA3 neurons (Fig. 8, A and B), 
notably without obvious cell loss at this early time point 
(Fig. 8 A). Systemic treatment with CSF1 significantly pre-
vented the loss of p-CREB immunoreactivity (Fig. 8, 
A and B) and p-CREB protein as measured by Western blot 
from hippocampal lysates (Fig. 8, C and D). Likewise, CSF1-
treated hAPP mice showed significantly higher p-CREB 
immunoreactivity in pyramidal neurons compared with PBS-
treated hAPP mice (Fig. 8, E and F). These results show that 
CSF1 can maintain CREB phosphorylation in neurons.
CSF1 and IL-34 activate the CREB pathway  
in primary neurons and protect against excitotoxic injury
The aforementioned results open the possibility that CSF1 
might act in part through neurons in our paradigm. To test 
the involvement of neuronal CSF1R signaling, we investi-
gated whether its ligands, CSF1 and IL-34 possess the capac-
ity to protect neurons from excitotoxicity in cell culture, in 
the absence of microglia. Indeed, incubation with CSF1 or 
IL-34 significantly increased p-CREB in primary neuronal 
culture as measured by Western blotting of cell lysates (Fig. 9 B). 
Importantly, NMDA-induced excitotoxic cell death was sig-
nificantly reduced by CSF1 or IL-34 (Fig. 9 C). Treatment of 
cells with GW2580 (Conway et al., 2005), a CSF1R kinase 
inhibitor, significantly blocked CSF1- or IL-34–mediated 
protection (Fig. 9 C). Moreover, exposure of hippocampal pri-
mary neurons to NMDA caused neuritic dystrophy, charac-
terized by the presence of varicosities and excessive tortuosity 
(Fig. 9 D). Assessment of dystrophy by visual criteria (Fig. 9 E) 
and by quantification of the neurite mean differential curvature, 
weaker but discernable reporter immunoreactivity was also 
seen in few, scattered neurons in the hippocampus (1.639 ± 
0.217%) throughout the brain (n = 3 mice/group), consistent 
with a recent publication using immunohistochemistry (Nandi 
et al., 2012). In the hippocampus, these neurons were ob-
served in the CA2/3 regions and in the dentate gyrus (Fig. 6 F). 
To determine whether CSF1R expression is increased after 
injury, we lesioned mice with KA and found that systemic or 
intrahippocampal administration of the glutamate receptor 
agonist leads to prominent up-regulation of the Csf1r reporter 
(Fig. 6, F–H). At 6 h after KA administration, reporter ex-
pression was increased not only in microglia but clearly also 
in neurons (36.52 ± 7.125%; n = 3 mice/group; Fig. 7, A–D). 
Although reporter expression continued to increase in mi-
croglia at 24 h and 5 d, it decreased in neurons (not depicted). 
The expression of CSF1R in neurons was also observed in 
separate lineage-tracing studies using crosses between Csf1r-iCre 
(Deng et al., 2010) and mTmG mice (Fig. 7 E; Muzumdar 
et al., 2007) or ROSA-stopflox-CFP mice (Srinivas et al., 
2001; not depicted). The Csf1r-iCre (Tg(Csf1r-icre)1Jwp) mice 
express an improved Cre (iCre) sequence under control of 
the Csf1r promoter (Deng et al., 2010). In the Csf1r-iCre and 
mTmG double transgenic reporter mice, cre recombinase 
expression in cells with an active Csf1r promoter results in 
expression of the membrane-targeted EGFP. Again, small 
numbers of neurons throughout the brain showed clear re-
porter gene expression (Fig. 7 E). The expression of Csf1r 
mRNA in neurons was further confirmed in cultured pri-
mary hippocampal neurons (see Fig. 9 A). Together, these 
results demonstrate that the CSF1R gene is expressed in neu-
rons and up-regulated after excitotoxic injury.
CSF1 maintains neuronal CREB phosphorylation
We next asked whether CSF1 might activate CSF1R-coupled 
intracellular pathways. Of these, CREB signaling appears to 
play a major role in mediating CSF1’s biological effects in 
macrophages (Casals-Casas et al., 2009). Importantly, KA 
Figure 5. Endogenous CSF1 is up-regulated in 
neurons after excitotoxic brain injury. (A–C) Wild-
type FVB/N or CSF1-null Csf1op/op mice (2 mo old) 
were lesioned with 20 mg/kg KA (subcutaneous injec-
tion) and sacrificed 6 h, 1 d, and 3 d later. Brain sec-
tions were immunostained with an antibody against 
CSF1. (A) Representative images from wild-type 
controls (no injury), KA lesioned and sacrificed at  
6 h, KA lesioned and sacrificed at 24 h, or Csf1op/op 
mice. (B) Quantification of CSF1 immunoreactivity in 
the hippocampus after KA injury (n = 4–6 mice/
group). Error bars indicate SEM. (C) Colocalization of 
CSF1 and neuronal marker NeuN but not microglial 
marker (Iba-1) after KA lesion (6 h). Bars: (A) 200 µm; 
(C) 20 µm. (D) Inverse correlation (Pearson correla-
tion) of CSF1 immunoreactivity with excitotoxic in-
jury assessed by cresyl violet staining. Results are 
from one out of two independent experiments.
164 CSF1 receptor signaling in neurons | Luo et al.
between uninjured Csf1rf/f-cre and littermate control brains 
(not depicted). To determine whether p-CREB immuno-
reactivity changes in response to KA injury, we stereotaxically 
injected PBS into the right and 50 ng KA into the left hippo-
campus. Mutant mice showed significantly reduced p-CREB 
immunoreactivity in the KA-injured side, whereas there was 
no difference in the PBS-injected side (Fig. 10, A and B). To 
investigate whether reduced CSF1R signaling is associated 
with increased susceptibility to neurodegeneration, we com-
pared Csf1rf/f-cre mice and their control littermates 5 d after 
stereotaxic injection of KA into the hippocampus. In spite 
of similar seizure severity between Csf1rf/f-cre and control 
mice (highest seizure score was 4.6 ± 1.5 in control vs. 4.9 ± 
1.7 in mutant mice), mutant mice died at twice the rate of 
control littermates (mortality was 16% in control vs. 30% in 
mutant, P = 0.042). Moreover, surviving Csf1rf/f-cre mice 
a measure of tortuosity (Fig. 9 F; Yang et al., 2008; Knowles 
et al., 2009), showed that CSF1 and IL-34 effectively blocked 
NMDA-induced dystrophy. Collectively, these results show 
that CSF1R ligands can activate CREB signaling and protect 
neurons against NMDA excitotoxic injury in vitro.
Depleting CSF1R in neurons increases  
susceptibility to excitotoxic injury
To further study the potential significance of neuronal CSF1R 
signaling in vivo, we deleted the receptor specifically in forebrain 
neurons. We generated CSF1R-null mutant mice (Csf1rf/f-cre) by 
breeding mice carrying a floxed exon 5 allele of the Csf1r 
gene (Csf1rf/f; Li et al., 2006) with CaMKII-cre transgenic 
mice (Fan et al., 2001). We first compared CREB phosphoryla-
tion in Csf1rf/f-cre mice and their control littermates. We did not 
observe significant differences in p-CREB immunoreactivity 
Figure 6. Expression of CSF1R in neurons. (A–D) Detec-
tion of Csf1r mRNA in the hippocampus using in situ hybrid-
ization. Wild-type FVB/N mice were lesioned with 20 mg/kg KA 
(subcutaneous injection) or injected with PBS as a control 
and sacrificed 24 h later. Brain sections were hybridized with 
DIG-labeled antisense (A and B) or sense (C and D) probes for 
Csf1r and developed with an anti-DIG antibody. No signal 
was detected with the sense probe (C and D). Arrows point 
to cells expressing CSF1R, as detected by in situ hybridiza-
tion. (E–H) CSF1R reporter mice (MAFIA mice, 2 mo of age) 
were lesioned with 20 mg/kg KA (subcutaneous injection) or 
injected with PBS as control and sacrificed 6 and 24 h later. 
These mice express an EGFP tag under the control of the 
Csf1r promoter so that the expression of CSF1R can be de-
tected by GFP immunostaining. (E) To test the specificity of 
the antibody against GFP, brain sections from MAFIA mice 
(not injured, left), wild-type mice (middle), and wild-type 
mice with KA injury (right) were immunostained. (F) Repre-
sentative images of different brain regions from MAFIA mice 
injected with PBS and sacrificed 24 h later (left) or injected 
with KA and sacrificed at 6 (middle) or 24 (right). (G) High-
magnification images showing GFP immunoreactivity in 
microglia (left) and neurons (middle and right), determined 
by morphology. Arrows point to cells expressing CSF1R, as 
detected by immunohistochemistry for the reporter gene. 
(H) 2-mo-old MAFIA mice received unilateral stereotaxic 
injections of 50 ng KA (right hemibrain) or PBS (left hemi-
brain). Mice were sacrificed 6 h later, and brain sections were 
analyzed for reporter gene expression by GFP immunostain-
ing. The data are representative of two independent experi-
ments with n = 3 mice/group. Bars: (A–D) 50 µm; (E, F, and H) 
200 µm; (G) 10 µm.
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Csf1rf/f-cre mice (Fig. 10, C and D). Similarly, calbindin immuno-
reactivity was depleted more severely in the CA1 subfield 
in KA-injected Csf1rf/f-cre compared with control littermates 
(Fig. 10, E and F). This increase in susceptibility to excitotoxic 
neurodegeneration in Csf1rf/f-cre mice was mirrored by an in-
crease in the microglial response. Microglial activation measured 
by CD68 and Iba-1 immunoreactivity was markedly increased 
in Csf1rf/f-cre compared with control mice (Fig. 10, G–J). In 
control mice, microgliosis was observed only on the ipsilateral 
side, whereas in Csf1rf/f-cre mice, it was also observed on the 
contralateral hippocampus (Fig. 10 G). In summary, mice lack-
ing CSF1R in neurons are more susceptible to death and 
neurodegeneration after excitotoxic injury, supporting a role 
for neuronal CSF1R signaling in their survival.
DISCUSSION
The present study demonstrates that CSF1R is up-regulated 
in injured neurons and contributes to the protection and in-
creased survival of these cells in vitro and possibly in vivo. We 
show that CSF1R ligands CSF1 and IL-34 are able to protect 
against excitotoxin-induced neurodegeneration and that CSF1 
ameliorates APP/A-mediated cognitive impairments. We also 
show that deletion of CSF1R in neurons exacerbates excito-
toxic injury and subsequent lethality and that up-regulation of 
endogenous CSF1 inversely correlates with neurodegeneration 
and neuroinflammation. Thus, CSF1R signaling supports the 
health and survival of neurons in our paradigms.
Our study provides several lines of evidence in support 
of a novel function for CSF1R signaling in neurons. First, 
CSF1R is expressed in neurons and up-regulated after brain 
injury. It was long held that the expression of CSF1R is 
restricted to cells of the monocyte/macrophage lineage and 
to microglia in the brain (Sherr et al., 1985; Raivich et al., 
1998), and recent studies using 7.2fms-EGFP reporter mice 
(C57BL/6N.Gn-Tg(Csf1r-EGFP)hume) lent further support 
to this notion (Sierra et al., 2007; Erblich et al., 2011). Al-
though Csf1r mRNA was detected by in situ hybridization in 
the brain (Murase and Hayashi, 1998; Wang et al., 1999), no 
functional expression of the receptor had been documented. 
Efforts to localize CSF1R protein expression in the brain 
using immunohistochemistry generated largely inconsistent 
and contradictory results (Murase and Hayashi, 1998; Raivich 
et al., 1998; Wang et al., 1999; Murphy et al., 2000). We think 
this was mainly caused by a lack of specific CSF1R antibodies 
as the six commercially available anti-CSF1R antibodies we 
tested failed to produce specific staining in the brain when 
tested in CSF1R knockout control mice. Instead, we demon-
strate neuronal CSF1R expression using two distinct reporter 
mouse models: one harboring a transgene consisting of the 
Csf1r promoter fused to EGFP (Figs. 6 and 7) and the other 
an icre recombinase inserted downstream of the Csf1r pro-
moter and crossed with EGFP reporter mice (Fig. 7). Both 
mouse models show expression of CSF1R in roughly 1–2% of 
neurons, but this expression was up-regulated after injury (Figs. 6 
and 7). In addition, primary neurons express Csf1r mRNA 
based on in situ hybridization. These results are consistent 
showed significantly more neurodegeneration and neuroin-
flammation than control littermates (Fig. 10). Although cell 
loss was restricted to the pyramidal cell layer of the CA3 re-
gion in control littermates (Fig. 10 C), it was more profound 
and widespread, spanning the whole CA3 and CA1 regions in 
Figure 7. CSF1R reporter gene is expressed in neurons and up-
regulated after excitotoxic brain injury. (A–D) CSF1R reporter mice 
(MAFIA mice, 2 mo of age) were lesioned with 20 mg/kg KA (subcutane-
ous injection) or injected with PBS as control and sacrificed 6 h later. 
Representative confocal microscopy images from control (PBS; A and C) 
and KA-lesioned mice (B and D) double immunolabeled with antibodies 
against GFP and cell type–specific markers Iba-1 (microglia; A and B) and 
NeuN (neurons; C and D). The reporter gene–expressing cells appear yel-
low after superimposition. An Iba-1 immuno-negative cell that expresses 
the reporter gene is shown (arrow) in A. Up-regulation of the reporter 
gene in neurons is shown after KA lesion (D) compared with control (C). 
The data are representative of two independent experiments with n = 3 
mice/group. (E) Csf1r-iCre mice were crossed with mTmG mice. Cre re-
combinase expression driven by the endogenous Csf1r promoter leads to 
expression of EGFP in double transgenic mice. Representative confocal 
microscopy images from control (PBS; left) and KA-lesioned mice (right)  
6 h after injury double immunolabeled with antibodies against GFP 
(green) and neuron-specific marker NeuN (blue). This experiment was 
performed once with n = 5 mice/group. Bars, 20 µm.
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the cre-lox system allowed us to specifically ablate the CSF1R 
in forebrain neurons, thus further linking CSF1R signaling 
to mature neurons.
Third, besides CSF1R itself, the ligand CSF1 also in-
creases in response to excitotoxic injury in neurons. 6 h after 
KA injection, strong induction of CSF1 is seen in CA3, the 
most sensitive region known to harbor neurons at risk of 
dying in this paradigm. Importantly, induction of CSF1 after 
injury seems to serve as a protective mechanism: mice that 
died within 6 h after KA administration showed no CSF1 
immunostaining, whereas mice that survived showed high 
levels of CSF1 expression. Interestingly, up-regulation of CSF1 
immunoreactivity in neurons has been noted before in re-
sponse to A and to focal brain injury (Du Yan et al., 1997; 
Takeuchi et al., 2001). Therefore, it is likely that CSF1 is 
produced in response to injury and may function as a protec-
tive system in neurons. Our experiments further suggest that 
at least part of this protective response involves signaling via 
CSF1R in injured neurons in addition to indirect neuropro-
tective effects mediated by microglia and other cells.
Fourth, IL-34, which is an independent, newly discovered 
CSF1R ligand, provides similarly potent neuroprotection as 
CSF1. IL-34 has so far not been examined for its function on 
cell types other than macrophages. In the brain, IL-34 mRNA 
was strongly expressed at E11.5, before the expression of Csf1 
mRNA (Wei et al., 2010). Interestingly, levels of IL-34 mRNA 
are higher than Csf1 mRNA in most regions of both the 
developing and adult brain (Wei et al., 2010), suggesting that 
IL-34 may have additional, nonoverlapping functions from 
with a recent publication showing that CSF1R is expressed in 
immature neurons during early postnatal development but is 
reduced in adult brain (Nandi et al., 2012).
Second, reducing neuronal CSF1R signaling by deleting 
CSF1R specifically in neurons resulted in increased neuro-
degeneration and mortality after excitotoxic injury (Fig. 10). 
Because CSF1 is known as a primary regulator for the mono-
cyte/macrophage lineage, the function of CSF1 in the brain 
was typically assigned to microglial regulation, and its role in 
neurons has not been established. Only a few studies pro-
posed effects of CSF1 on neurons based either on cell culture 
experiments in which CSF1 enhanced survival of Purkinje 
cells and reduced apoptotic neuron death (Murase and 
Hayashi, 1998; Wang et al., 1999) or on using a model of 
stroke whereby peripheral administration of CSF1 reduced 
infarct size and increased neuronal survival (Berezovskaya 
et al., 1996). CSF1-deficient Csf1op/op mice showed increased 
neuronal vulnerability to ischemic and chemical-induced 
damage (Berezovskaya et al., 1995; Penkowa et al., 2002). 
In addition, the Csf1op/op and CSF1R knockout mice showed 
abnormal brain development (Michaelson et al., 1996; 
Erblich et al., 2011), but it remained unclear whether these 
phenotypes involved CSF1R signaling in neurons. Deleting 
CSF1R in neural progenitor cells partially recapitulated the 
forebrain phenotypes of Csf1op/op and CSF1R knockout 
mice (Nandi et al., 2012), suggesting that lacking CSF1R 
signaling in immature neurons contributes to CSF1R- 
mediated brain developmental abnormalities of the Csf1op/op 
and CSF1R knockout mice. Our genetic experiments using 
Figure 8. CSF1 maintains CREB phosphoryla-
tion. (A–D) CSF1 maintains CREB phosphorylation 
after KA lesion. Wild-type FVB/N mice (n = 4 per 
group, 2 mo of age) were lesioned with 20 mg/kg KA 
(subcutaneous injection) or injected with PBS as con-
trol. For treatment, CSF1 or PBS was applied 24 h 
before KA. Mice were sacrificed 6 h after KA injection. 
One hemibrain was fixed for immunohistochemistry 
with an antibody against p-CREB (A, left and middle), 
and p-CREB immunoreactivity was quantified as 
percentage of area occupied (B). The opposite hippo-
campi were isolated and subjected to Western blot 
analysis for p-CREB (C), which was quantified as 
optical intensity (D). Results are from one out of two 
independent experiments. (E and F) CSF1 restores 
CREB signaling in hAPP mice. hAPP mice and their 
nTG littermates (Fig. 1 A) were treated with 800 µg/kg 
CSF1 or PBS three times a week. 10 wk later, the mice 
were sacrificed after water maze behavior test, and 
one hemibrain was analyzed by immunohistochemis-
try for p-CREB immunoreactivity. The experiment was 
performed once. Error bars indicate SEM. Bars:  
(A, left) 200 µm; (A [middle and right] and E) 50 µm. 
*, P < 0.05; **, P < 0.01 compared by ANOVA and 
Bonferroni post-hoc test (B and F) or Student’s t test (D).
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cognitive function (Kandel, 2001; Lonze and Ginty, 2002), 
the induction and activation of the CREB pathway in neu-
rons may explain at least part of the robust survival effects of 
CSF1 and IL-34. How CSF1 and IL-34 activate the CREB 
pathway in neurons needs further investigation. In macro-
phages, CSF1-coupled signaling leads to activation of PKA 
and cAMP (Majumdar et al., 2007), both of which can in-
duce CREB phosphorylation, and it is conceivable that 
CSF1 activates the CREB pathway through similar mecha-
nisms in neurons.
Although our experiments suggest a novel role for CSF1R 
signaling in protecting neurons against injury, it is likely that 
independent or synergistic effects on other CNS cell types 
contribute to the potent in vivo effects of CSF1 and IL-34. 
For example, CSF1 may modulate inflammatory responses in 
microglia or astrocytes which play an important role in neurode-
generation (Wyss-Coray, 2006). Besides neurons and microg-
lia, CSF1R mRNA has been detected in cultured astrocytes 
and oligodendrocytes using RT-PCR (Sawada et al., 1993), 
although CSF1R was not up-regulated in these cells in the 
reporter mice in our paradigm (Figs. 6 and 7).
CSF1 in the brain (Hamilton and Achuthan, 2012). Results 
from a recent cell fate mapping study support this notion and 
provide indirect evidence for an important role of IL-34 in the 
regulation of microglial homeostasis (Ginhoux et al., 2010). In-
terestingly, IL-34–deficient reporter mice revealed that neurons 
are the main sources of IL-34 (Wang et al., 2012). Intracere-
broventricular administration of IL-34 ameliorated impairment 
of associative learning and reduced A levels in an APP/PS1 
transgenic mouse model of AD, although these effects were 
ascribed to microglia and direct effects on neurons were not 
studied (Mizuno et al., 2011).
Lastly, administration of recombinant CSF1 or IL-34 
protected cultured primary neurons from excitotoxic injury 
and induced the phosphorylation of CREB, consistent 
with previous reports that CSF1 enhanced survival and neu-
rite outgrowth of neurons cultured in serum-free medium 
(Michaelson et al., 1996; Murase and Hayashi, 1998; Wang 
et al., 1999). In addition, CSF1 administration reduced the 
loss of p-CREB in response to KA or APP/A transgene 
in vivo. Because CREB signaling has been implicated in 
promoting neuronal survival and in memory formation and 
Figure 9. Recombinant CSF1 and IL-34 inhibit excitotoxic 
injury and activate the CREB pathway in vitro. (A) Detection 
of Csf1r mRNA by in situ hybridization in cultured primary 
neurons. Primary hippocampal neurons were isolated from 
16-d-old CF1 mouse embryos, aged for 6–7 d and hybridized 
with DIG-labeled Csf1r sense (top) or antisense (bottom) 
probes. (B–F) Primary hippocampal neurons were isolated from 
16-d-old CF1 mouse embryos and were aged for 6–7 d (B and C) 
or 21–22 d (D–F). (B) Primary neurons were exposed to 1 or  
100 ng/ml IL-34, 1 or 100 ng/ml CSF1, 10 µM Forskolin (FSK, as a 
positive control), or PBS (as a negative control) for 30 min. The 
cells were lysed and subjected to Western blot analysis for  
p-CREB. (C–F) Primary neurons were challenged with 100 µM 
NMDA in the presence and absence of CSF1 or IL-34 (both at  
10 ng/ml) and assayed for neurotoxicity (C) or neuritic dystrophy 
(D–F), respectively. For inhibitor experiments, 10 µM GW2580 
was coincubated with CSF1 or IL-34. (C) Live and dead cells were 
counted according to their morphologies determined by phase-
contrast microscopy. Results are expressed as percentage of live 
cells. (D–F) Neurons were fixed and immunostained for MAP-2 
to visualize dendrites. Dystrophic neurites in NMDA-treated 
cultures show increased tortuosity, exhibiting multiple abrupt 
turns (D, bracket). The number of dystrophic neurites (E) and 
their mean differential curvature (F) are reduced with CSF1 or IL-34 
treatment. Error bars indicate SEM. Bars, 20 µm. *, P < 0.05;  
**, P < 0.01 compared by ANOVA and Tukey’s post-hoc test. The 
experiments were independently performed five times for B and 
twice for the rest with triplicates of each group.
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A key finding from our study and one of potential clinical 
relevance is that CSF1 and IL-34 produce strong neuropro-
tective and survival effects in the brain even if adminis-
tered systemically several hours after a neuronal insult. Using 
in vivo bioluminescence imaging, we demonstrate that CSF1 
administered 2 or 6 h after injury exerts similar benefits to 
neuronal survival as CSF1 delivered before injury (Fig. 2). In 
addition, in vivo imaging of astrocyte activation showed that 
the initial injury/insult was similar (shown by similar levels of 
astrogliosis at day 1) whether CSF1 was given before or after 
injury but that the outcome was affected (shown by reduced 
levels of astrogliosis at days 3 and 5). These results suggest that 
CSF1 may promote the postinjury survival of neurons rather 
than reducing the initial insult. How exactly systemic CSF1 
reaches CNS neurons remains to be determined, but it is pos-
sible that the blood–brain barrier is impaired early after KA 
injury (Saija et al., 1992; Pont et al., 1995).
Our findings place the hematopoietic factors CSF1 and 
IL-34 among several important neuroprotective factors and 
support the growing view that hematopoietic and other clas-
sical immune factors may have equally important functions in 
the CNS (Maurer et al., 2008). The findings provide a ge-
netically based, mechanistic framework on how CSF1, a clas-
sical immune factor assigned to macrophage function, protects 
neurons. Because CSF1 is approved for human use in clinical 
trials (Douglass et al., 2008; Hume and MacDonald, 2012), it 
may be an attractive therapeutic candidate for brain injury and 
neurodegenerative disorders.
MATERIALS AND METHODS
Mice. The following transgenic mouse lines were used: hAPP mice (line 41) 
expressing mutated (London V717I and Swedish K670M/N671L) human 
APP751 under the control of the mouse Thy1 promoter (Rockenstein et al., 
2001), GFAP-luc mice (Caliper Life Science; Zhu et al., 2004), CSF1-null 
Csf1op/Csf1op mice (The Jackson Laboratory; Wiktor-Jedrzejczak et al., 1990; 
Yoshida et al., 1990), actin-EGFP (C57BL/6-Tg(ACTB-EGFP)1Osb/J) mice 
expressing EGFP under the control of a chicken -actin promoter (The Jackson 
Laboratory; Okabe et al., 1997), CaMKII-cre mice (obtained from R. Jaenisch, 
Massachusetts Institute of Technology, Cambridge, MA; Fan et al., 2001), 
Csf1r-iCre (Tg(Csf1r-icre)1Jwp) mice expressing an iCre sequence under control 
of the Csf1r promoter (Deng et al., 2010), ROSA-stopflox-CFP mice (Srinivas 
et al., 2001), mTmG mice (Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP); The Jackson 
Laboratory; Muzumdar et al., 2007), Csf1rf/f mice (Csf1rtm1Lex5jwp, carrying a 
floxed exon 5 allele of the Csf1r gene; Li et al., 2006), and Csf1r-deficient mice 
(deleted in exon 5 of the Csf1r gene; Li et al., 2006). Csf1r f/f mice were crossed 
with CaMKII-cre mice to generate forebrain neuron–specific CSF1R-null 
mutant mice (CaMKII-cre+; Csf1r f/f, named Csf1rf/f-cre in this study). Csf1r-iCre 
mice were crossed with ROSA-stopflox-CFP mice or mTmG mice to label 
Csf1r-expressing cells. CSF1R reporter (C57BL/6J-Tg(Csf1r-EGFP-NGFR/
FKBP1A/TNFRSF6)2Bck/J, synonym: macrophage Fas–induced apoptosis 
[MAFIA]) mice (Burnett et al., 2004) expressing EGFP under control of the 
Csf1r promoter were purchased from the Jackson Laboratory under agreement 
with Ariad Pharmaceuticals. The hAPP, Csf1rf/f, CaMKII-cre, and MAFIA 
mice were on a C57BL/6 genetic background, and GFAP-luc mice were on an 
Figure 10. Deletion of CSF1R in neurons reduces p-CREB immuno-
reactivity and increases susceptibility to excitotoxic injury.  
Csf1rf/f-cre mice and their control littermates (2 mo of age) were lesioned 
with a unilateral stereotaxic injection of 50 ng KA or PBS as control into 
the hippocampus. (A and B) Mice were sacrificed 24 h later, and brain 
sections were analyzed for p-CREB immunoreactivity, quantified as per-
centage of area occupied (n = 3 mice/group). The boxes in A indicate the 
corresponding hippocampal areas shown in the panel below (with higher 
magnification). (C–J) Mice were sacrificed 5 d later, and brain sections 
were analyzed for neuronal injury by cresyl violet staining (C and D), cal-
bindin immunostaining (E and F), and CD68 or Iba-1 immunostaining 
(microglial activation; G–J). In C, E, G, and I, mice from the control (top) 
and Csf1rf/f-cre mice (bottom) are shown. Bars, 200 µm. Bars are mean ± 
SEM (n = 3–4 mice/group) from one out of two independent experiments.  
*, P < 0.05; **, P < 0.01 compared with control by Student’s t test.
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administered separately into both parabionts of each pair starting at week 2 
(hAPP parabionts received CSF1 for 5 wk). For KA injury, actin-EGFP mice 
were crossed with FVB/N mice to increase susceptibility, and F1 mice were 
used for experiments. Both parabionts of each pair were lesioned with KA 
at 5 wk after surgery. CSF1 was injected (i.p.) 24 h before KA.
Tissue processing. Mice were anesthetized with 400 mg/kg chloral hy-
drate (Sigma-Aldrich) and transcardially perfused with 0.9% saline (Luo 
et al., 2006, 2007). Brains were removed and divided sagittally. One hemi-
brain was postfixed in phosphate-buffered 4% paraformaldehyde (PFA), pH 
7.4, at 4°C for 48 h and sectioned at 40 µm with a Vibratome 2000 (Leica) 
and stored in cryoprotective medium; the other hemibrain was snap frozen 
and stored at 80°C for biochemical analysis (Luo et al., 2006, 2007).
Western blotting. Snap-frozen hippocampi were lysed in 200 µl RIPA 
lysis buffer (500 mM Tris, pH 7.4, 150 mM NaCl, 0.5% Na deoxycholate, 
1% NP-40, 0.1% SDS, and complete protease inhibitors; Roche; Lin et al., 
2005). Tissue or 20 µl of cell lysates was mixed with 4× NuPage LDS load-
ing buffer (Invitrogen) and loaded on a 3–12% SDS-polyacrylamide gradient 
gel and subsequently transferred onto a polyvinylidene fluoride membrane. 
The blot was incubated with rabbit polyclonal antibodies against p-CREB 
(1:1,000; Cell Signaling Technology) and an HRP-conjugated secondary 
antibody (GE Healthcare). Protein signals were detected using an ECL 
kit (GE Healthcare).
ELISA analysis of A. For cerebral A levels, snap-frozen hippocampi 
and cortices were homogenized in RIPA buffer followed by 70% formic 
acid at 0.1 mg weight tissue per 1 ml. A peptides were quantified by 
ELISA as described previously (Pickford et al., 2008) using 5 µg/ml antibody 
266 (A13–28; Elan Pharmaceuticals) as the capture antibody for total A1-x or 
5 µg/ml antibody 21F12 (A37–42; Elan Pharmaceuticals) as the capture anti-
body for Ax–42 and 2 µg/ml of biotinylated 3D6 (A1–5; Elan Pharmaceuti-
cals) as the detection antibody. After incubation with the secondary antibody, 
samples were incubated with avidin-HRP (diluted 1:4,000; Vector Labora-
tories), and the signal was developed using 1-step Turbo TMB ELISA solu-
tion (Thermo Fisher Scientific).
Cresyl violet staining. Brain sections were mounted on Superfrost plus 
slides (Thermo Fisher Scientific), air-dried, rehydrated, stained with 0.02% 
cresyl violet (Sigma-Aldrich) in acetate buffer, pH 3.2, then dehydrated 
through a series of alcohols, cleared in xylene, and coverslipped (Luo et al., 
2006). Neuronal damage/loss was assessed based on the appearance of gaps 
or thinning and disappearance of the Nissl substance in the CA1 and CA3 
pyramidal cell layers. The lesion area was quantified with MetaMorph Imag-
ing software (Molecular Devices).
Immunohistochemistry, image analysis, and confocal microscopy. 
Immunohistochemistry was performed on free-floating sections according 
to standard procedures (Luo et al., 2006, 2007). Primary antibodies were 
against 3D6 (biotinylated; Elan Pharmaceuticals), Calbindin (1:10,000; EMD 
Millipore), CD68 (1:50; AbD Serotec), Iba-1 (1:2,500; Wako Chemicals 
USA), CD11b (1:200; Abcam), NPY (1:200; EMD Millipore), CSF1 (1:2,000; 
R&D Systems), p-CREB (Ser 133; 1:1,000; EMD Millipore), and GFP 
(1:1,000; Invitrogen). Six anti-CSF1R antibodies were obtained (two from 
Santa Cruz Biotechnology, Inc., two from EMD Millipore, one from Cell 
Signaling Technology, and one from Biogen Idec, generated by New England 
Peptide, sequence Ac-DPESPGSTC-amide) and tested with brain sections 
from Csf1r knockout mice (Li et al., 2006). After overnight incubation, pri-
mary antibody staining was revealed using biotinylated secondary antibodies 
and the ABC kit (Vector Laboratories) with diaminobenzidine (Sigma-Aldrich) 
or fluorescence-conjugated secondary antibodies. Photographs were acquired 
using a BX51 microscope (Olympus) and a SPOT Flex shifting pixel charge-
coupled device camera with SPOT Advanced software (SPOT Imaging Solu-
tions). The immunoreactivity was quantified as the percentage of area covered by 
MetaMorph software (version 7) as previously described (Luo et al., 2006, 2007). 
FVB/N background. The following mice were used as controls for mutants: 
nTG littermates for hAPP and actin-EGFP, wild-type C57BL/6 for Csf1op/op, 
and CaMKII-cre-;Csf1r f/f littermates (Cre-) for Csf1rf/f-cre. Wild-type FVB/N 
or C57BL/6 mice were purchased from the Jackson Laboratory. Animal han-
dling was performed in accordance with institutional guidelines and approved 
by a local Institutional Animal Care and Use Committee.
KA-induced excitotoxicity. For FVB/N mice, KA (Tocris Bioscience) was 
dissolved in distilled water and injected subcutaneously (20 or 30 mg/kg) to 
induce neurodegeneration (Luo et al., 2006). Seizure activity was monitored 
every 15 min for 1 h after KA administration, using a scoring system from 0 to 8, 
with 0 showing no behavioral changes and 8 showing death (Janumpalli 
et al., 1998). For C57BL/6 mice, 0.50 µl KA (0.1 µg/µl) was injected stereo-
taxically unilaterally into the hippocampus (coordinates from bregma: A = 
2.0 mm and L = 1.8 mm; from brain surface: H = 2.0 mm) under iso-
flurane anesthesia. KA was injected over 2 min using a 5-µl Hamilton syringe. 
After injection, the needle was maintained in situ for an additional 2 min to 
limit reflux along the injection track. The skin was closed using adhesive surgi-
cal block, and each mouse was injected subcutaneously with Buprenex as di-
rected for pain relief. Animals were examined 5 d after KA injection. In some 
experiments, to study how expression of endogenous CSF1 and the receptor 
changes in response to KA, animal mice were analyzed at different time points 
(6 h, 24 h, 3 d, and 5 d) after KA administration.
CSF1 and IL-34 treatment. Recombinant human CSF1 was provided by 
Biogen Idec. Recombinant mouse IL-34 was purchased from R&D Systems. 
CSF1 was injected i.p. at 800 µg/kg body weight, a dose previously used 
clinically in bone marrow transplantation patients (Nemunaitis et al., 1993). 
IL-34 was injected i.p. at 100 µg/kg body weight. The same volume of PBS 
was used as a control treatment. For hAPP mice, CSF1 was injected i.p. three 
times a week. For kainate injury, CSF1 or IL-34 was injected i.p. once at 
different time points in relation to kainate injury.
Behavioral tests for hAPP mice. We used the Morris water maze to assess 
the effect of CSF1 on spatial learning and memory (Adlard et al., 2005). In 
brief, after training the mice with a visible platform, animals were subjected 
to 6 d of place discrimination training using a hidden platform, with four 
trials per day, followed by a probe trial 24 h later to assess retention of the 
task. Data were analyzed using the Ethovision automated tracking system 
(Noldus Information Technology).
In vivo bioluminescence imaging. Bioluminescence was detected with 
the In Vivo Imaging System (IVIS Spectrum; Caliper Life Science; Lin 
et al., 2005; Luo et al., 2006, 2007). Mice were injected i.p. with 150 mg/kg 
d-luciferin 10 min before imaging and anesthetized with isoflurane during 
imaging. Photons emitted from living mice were acquired as photons/s/cm2/
steridian (sr) using LIVINGIMAGE software (version 3.1) and integrated over 
3 min. For photon quantification, a region of interest was manually selected 
and kept constant for all experiments; the signal intensity was converted into 
photons/s/mm2/sr. For longitudinal comparison of bioluminescence, baseline 
imaging was performed 24 h before KA was administered, and biolumines-
cence was expressed as fold induction over baseline levels for each mouse.
Parabiosis. Actin-EGFP mice were surgically connected with their nTG lit-
termates or hAPP mice to produce parabiosis, as previously described (Villeda 
et al., 2011). In brief, pairs of mice were anesthetized and prepared for surgery. 
Mirror-image incisions at the left and right flanks, respectively, were made 
through the skin. Shorter (1 cm) incisions were made through the abdomi-
nal wall. The abdominal openings were sutured together, and the skin of each 
mouse was stapled (9-mm Autoclip; Clay Adams) to the skin of its parabiont, 
thereby closing the incision. Each mouse was injected subcutaneously with 
Baytril antibiotic and Buprenex as directed for pain and monitored during 
recovery. Blood circulation was established after 2 wk, and the non-
GFP–expressing (nTG or hAPP) parabionts were analyzed for GFP+ cells in 
the brain at 6 wk after surgery. To study the effects of CSF1, CSF1 or PBS was 
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used to compare pairs of groups after ANOVA. Statistical analysis was per-
formed with Prism software (version 5; GraphPad Software). P < 0.05 was 
considered statistically significant.
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